CeleramAb provides kits and software to enable the detailed molecular characterization of antibodies by direct infusion mass spectrometry. Their proprietary technology can map oxidation, deamidation, glycosylation and drug conjugation sites within 45-90 seconds with similar precision and accuracy as conventional LC-MS-based peptide mapping.